A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Miami
St. Jude Children's Research Hospital
Tianjin Medical University Cancer Institute and Hospital
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
University of Chicago
Tianjin Medical University Cancer Institute and Hospital
Mayo Clinic
Case Comprehensive Cancer Center
Icahn School of Medicine at Mount Sinai
M.D. Anderson Cancer Center
Hellenic Society of Hematology
M.D. Anderson Cancer Center
Ciusss de L'Est de l'Île de Montréal
M.D. Anderson Cancer Center
Stanford University
Stanford University
Stanford University
Virginia Commonwealth University
University of South Florida
M.D. Anderson Cancer Center
Duke University
Isfahan University of Medical Sciences